Alzheimer's drug trial pulled before it even started
NCT ID NCT02467413
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to test a drug called BAC in people with Alzheimer's disease or vascular dementia. The goal was to see if it could improve thinking and memory, and to check for side effects. However, the trial was withdrawn before any participants were enrolled, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cheng Kung University Hospital
Tainan, 704, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an antibody slow Alzheimer's? a new trial seeks answers
- Can tracking thousands of dementia cases reshape how we care for patients?
- Psilocybin and brain training: a new frontier for aging minds?
- Mining medical claims: a smarter way to spot Alzheimer's complications?
- Could an antibody stop Alzheimer's before it starts?
- Could a Finger-Prick test detect Alzheimer's at home?